Enox Biopharma, Inc. Will Be Granted its Foundation Patent

VANCOUVER, British Columbia, Aug. 22, 2011 /PRNewswire/ — Enox
Biopharma, Inc., a leader in the development of innovative
solutions for infections associated with medical devices, today
announced that it has received a notice of allowance from the US
Patent Office that its patent application entitled “Antimicrobial
Gas-Releasing Ear Drainage Tubes” has been approved and a patent
will granted.

This patent was the first applied for by Enox and is the
foundation patent of the company. The notice of allowance for this
patent underscores the novelty of Enox’s technology which utilizes
nitric oxide gas embedded into polymers as an antimicrobial to
prevent hospital acquired infections. Nitric oxide is well
recognized as an ideal antimicrobial agent that is highly effective
yet free from the drug resistance issues that have resulted from
excessive antibiotic use. Additional patent applications, which are
under review in the United States and in countries around the
world, expand the use of antimicrobial gas releasing technology to
virtually any polymer-based medical device.

“This is a very significant patent for Enox. Not only does it
solidify our intellectual property portfolio, it is rigorous
external validation of our technology being the first of its kind.
With our foundation patent issued, the probability of our other
intellectual property applications being successful is increased,”
stated Enox CEO, John Rewcastle, Ph.D. “Nitric oxide emitting
medical devices have a unique potential to reduce hospital acquired
infections which are a global problem costing tens of billions of
dollars annually. The issuance of this patent further ensures Enox
is the only company that can create such devices.”

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with
proprietary methods to sequester nitric oxide (NO) into polymers.
The innate immune system uses NO to block microbial growth –
embedding NO into medical devices

‘/>”/>

SOURCE